Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,582 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 31, 2026, 12:45 AM EDT
Recruiting Not applicable Interventional

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

NCT04873037
View directory record Official record
Conditions
Overactive Bladder Syndrome, Overactive Bladder, Urinary Frequency, Urinary Urgency
Interventions
BTL Emsella Chair, Sham BTL Emsella Chair
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Completed No phase listed Observational

The Women's Urology Center/WISH Database Project

NCT00379002
View directory record Official record
Conditions
Interstitial Cystitis, Sexual Dysfunction, Pelvic Pain, Incontinence
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
2,923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 31, 2026, 12:45 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility of HISA During TURBT for NMIBC

NCT07817173
View directory record Official record
Conditions
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms, Non-muscle Invasive Bladder Cancer, Bladder Cancer (BC), Transurethral Resection of Bladdertumors, Transurethral Resection of the Bladder, Non-Muscle Invasive Bladder Carcinoma
Interventions
HISA
Device
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Urge Incontinence Bladder Overactivity Study

NCT00475696
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2007 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Recruiting Not applicable Interventional

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

NCT07225205
View directory record Official record
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 4 Interventional

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

NCT00224146
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence, Quality of Life
Interventions
oxybutynin transdermal delivery system (Oxytrol(r))
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Mobile, Alabama • Tucson, Arizona • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 31, 2026, 12:45 AM EDT
Recruiting Phase 1 Interventional

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT06963346
View directory record Official record
Conditions
Bladder Cancer
Interventions
Romidepsin, Durvalumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Recruiting Not applicable Interventional

Investigation of PEMF Therapy for Female Patients With IC/BPS

NCT05149573
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Pulsed Electromagnetic Field (PEMF) Device, Sham Pulsed Electromagnetic Field (PEMF) Device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated Not applicable Interventional Results available

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

NCT00147238
View directory record Official record
Conditions
Bladder Cancer, Genitourinary Cancer, Prostate Cancer
Interventions
Ferumoxtran-10 (USPIO), MR lymphangiography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Not applicable Interventional

Absorbable Suture vs Permanent Suture in Sacrospinous Ligament Suspension

NCT05688059
View directory record Official record
Conditions
Pelvic Organ Prolapse, Uterovaginal Prolapse, Vaginal Vault Prolapse, Cystocele
Interventions
Absorbable Suture and Permanent Suture
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

NCT06567743
View directory record Official record
Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec
Drug
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
79
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated Not applicable Interventional

Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy

NCT04305379
View directory record Official record
Conditions
Prostate Cancer, Urinary Incontinence, Surgery
Interventions
Augmented Bladder Neck Reconstruction, Standard Bladder Neck Reconstruction
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
Drug · Other · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study

NCT04016324
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
Interventions
InterStim Basic Evaluation lead and foramen needle
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
St. Petersburg, Florida • Tampa, Florida • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 2Phase 3 Interventional

Celecoxib in Treating Patients With Bladder Cancer

NCT00006124
View directory record Official record
Conditions
Recurrent Bladder Cancer
Interventions
celecoxib, placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 31, 2026, 12:45 AM EDT
Completed No phase listed Observational

IFACT: Incidental Findings in Advanced Cancer Therapy

NCT02217891
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Bladder Cancer, Lung Cancer
Interventions
Semi-structured interview
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

NCT05085990
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 31, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mapping of the Human Brainstem During Continence and Micturition: Noninvasive 7-T fMRI Study

NCT04846387
View directory record Official record
Conditions
Healthy
Interventions
Magnetic Resonance Imaging (MRI), Post-Void Residual, Uroflowmetry, Questionaire - AUA Symptom Score
Diagnostic Test · Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Adverse Childhood Experiences in Urogynecologic Patients

NCT03480477
View directory record Official record
Conditions
Pelvic Floor Disorders, Interstitial Cystitis, Urinary Incontinence
Interventions
ACE questionnaire
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 31, 2026, 12:45 AM EDT